Recursion Pharmaceuticals Inc.
Clinical trials sponsored by Recursion Pharmaceuticals Inc., explained in plain language.
A clinical-stage biotech using AI to discover and develop drugs.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Cancer drug trial halted: REC-4881 fails to show promise in Gene-Mutated tumors
Disease control TerminatedThis study tested a daily pill called REC-4881 in 18 adults aged 55+ with advanced solid tumors that had AXIN1 or APC gene mutations. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising c. diff drug trial halted after just 3 patients
Disease control TerminatedThis study tested a new drug called REC-3964 to see if it could prevent repeat Clostridioides difficile (C. diff) infections in adults. Only 3 people were enrolled before the trial was stopped early. The goal was to check safety and whether the drug helped people stay infection-f…
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental drug REC-2282 targets NF2 brain tumors in early trial
Disease control TerminatedThis study tested a drug called REC-2282 in people aged 12 and older with progressive meningiomas (brain tumors) linked to NF2 gene mutations. Participants took the drug or a placebo three times a week in cycles. The goal was to see if the drug could slow tumor growth. The trial …
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC